Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 11, Issue 6, 2009, Pages 571-578

  Rosenstock, Julio ^a   Niggli, M ^b   Maldonado Lutomirsky, M ^b  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Lipids; Oedema; Rosiglitazone; Sustained HbA1c; Type 2 diabetes mellitus; Vildagliptin; Weight gain

Indexed keywords

HEMOGLOBIN A1C; LIPID; ROSIGLITAZONE; VILDAGLIPTIN;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 65549109984     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01021.x     Document Type: Article

References (29)

1. Villhauer EB, Brinkman JA, Naderi GB et al. 1-(3-Hydroxy-1-adamantyl)am ino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-2789.
2. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423-428.
3. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138.
4. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007; 30: 217-223.
5. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084. Metab 2004; 89: 2078-2084.
6. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
7. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.
8. Schlessmann LS. Vildagliptin, a dipeptidyl peptidase-lV inhibitor for the treatment of type 2 diabetes. Formulary 2006; 41: 494-500.
9. Del Prato S. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. Int J Clin Pract 2007; 61 (Suppl. 154): 38-48.
10. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
11. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115 (Suppl. 8A): 42S-48S.
12. Cheng AYY, Fantus IG. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother 2004; 38: 817-820.
13. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
14. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 2004; 27: 256-263.
15. Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007; 76: 279-289.
16. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ 2002; 166: 219.
17. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
18. Dahabreh IJ. Meta-analysis of rare events: An update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5: 116-120.
19. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
20. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-3354.
21. Scherbaum WA, Schweizer A, Mari A et al. Evidence that vildagliptin attenuates deterioration of glycemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008; 10: 1114-1124. doi: 10.1111/j.1463-1326.2008.00875.x.
22. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over one year. Diabetes Care 2005; 28: 1936-1940.
23. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
24. Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
25. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
26. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005; 102: 9406-9411.
27. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes Obes Metab 2006; 9: 166-174.
28. Comi RJ. Treatment of type 2 diabetes mellitus: A weighty enigma. Ann Intern Med 2005; 143: 609-610.
29. Shim WS, Do MY, Kim SK et al. The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol 2006; 65: 453-459.